Pre-BCG peri-tumoral TLSs, from our study, on the cover of October, 2025 issue!!! Beautiful artwork (a storm exhausting the immune cell cluster in BCG unresponsive NMIBC tumors) by Lewis Long. Thank you Cancer Immunology Research !!! aacrjournals.org/cancerimmunolr…

⚡️ Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy #BladderCancer Mohammad Jad Moussa, MD, MSc Omar Alhalabi, MD Pavlos Msaouel ⁩ Matt Campbell MD, MS mdpi.com/1718-7729/31/6… ⁩ ⁦

⚡️ On European Urology - Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma #BladderCancer Iver Nordentoft Sia Viborg Lindskrog europeanurology.com/article/S0302-…

In nature: Full text article "Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer." Click here to read it: nature.com/articles/s4159…

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. 👇

⚡️ Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial #BladderCancer Priyamvada Maitre Vedang Murthy sciencedirect.com/science/articl…

Happy to present the latest review in Bladder Cancer by Sandeep Gurram and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing ✅Rationale for devices ✅Devices available ✅Mechanisms ✅Efficacy ✅Safety ✅Future Studies

New Research Report: A molecular urine assay to detect recurrences during surveillance of high-risk non-muscle invasive bladder cancer by Christiaan de Jong, Joep J. de Jong, et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

NEW REVIEW focusing on ctDNA👉Perioperative use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now👈by DrTylerStewart et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… Toni Choueiri, MD Dr. Bishoy M. Faltas splernerMD

POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by Ronald Chen, splernerMD, Guru P. Sonpavde, MD, Himanshu Nagar, Parminder singh et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… Dr. Bishoy M. Faltas Dan Theodorescu

SHORT COMMUNICATION: Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists by Ivy Beeren et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

RESEARCH REPORT: Effectiveness of prolonged antibiotic prophylaxis in radical cystectomy: preliminary analysis of the MACS randomized clinical trial by Mariya Berkut et al. pmc.ncbi.nlm.nih.gov/articles/PMC11…. Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

🔥NOW in Bladder Cancer of Bladder Cancer Advocacy Network👉Can Combining ICIs w/ Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer? Omar Alhalabi, MD MD Anderson Cancer Center 1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed. Better patient selection🔑?

Research Report: Repeat TURBT in large volume HG Ta NMIBC treated with induction BCG therapy was not associated with improved high-risk recurrence-free survival. Adri Durant et al. journals.sagepub.com/doi/full/10.11…. Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

RESEARCH REPORT: North American Study and Meta-analysis Evaluating Performance of Bladder EpiCheck®, a FDA cleared test, in Non-Muscle Invasive Bladder Cancer Recurrence by Neil Fleshner et al. journals.sagepub.com/doi/full/10.11… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

⚡️ On European Urology - Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure. - Feasible administration with negligible toxicity. - Encouraging efficacy as a localized immune checkpoint inhibitor. - Intravesical delivery may surpass

REVIEW: Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: evaluating treatment outcomes by Vera Rutten et al. journals.sagepub.com/doi/10.1177/23… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

The First Systematic Review and Meta-Analysis of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors in Urothelial Cancer: Efficacy, Clinical Use and Future Applications by Mohammad Jad Moussa, MD, MSc et al. journals.sagepub.com/doi/full/10.11… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

SHORT COMMUNICATION: Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies by Yelba Castellon-Lopez and Patricia Thompson. journals.sagepub.com/doi/full/10.11… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD

RESEARCH REPORT: BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis by Zine-Eddine KHENE et al. journals.sagepub.com/doi/10.1177/23… Dr. Bishoy M. Faltas Dan Theodorescu splernerMD